Endogenex is a clinical stage company focused on improving outcomes and quality of life for patients living with Type 2 Diabetes (T2D). Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D.
Location: United States, Minnesota, Plymouth
Employees: 11-50
Total raised: $12M
Founded date: 2017
Investors 3
| Date | Name | Website |
| 26.10.2023 | Lumira Ven... | lumiravent... |
| - | Intuitive ... | ventures.i... |
| 22.06.2021 | Longitude ... | longitudec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.04.2021 | - | $12M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 01.02.2024 | Endogenex Receives IDE Approval to Initiate Pivotal Clinical... | A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System ... | lumiravent... |
| 30.01.2024 | Endogenex Receives IDE Approval to Initiate Pivotal Clinical... | A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System ... | en.prnasia... |